癌症患者生命质量测定量表体系之脑肿瘤量表QLICP-BN的测量学评价

Metric evaluation of quality of life instruments for cancer patients-brain neoplasm(QLICP-BN)

目的了解自主研制的癌症患者生命质量测定量表体系之脑肿瘤量表QLICP-BN(V1.0)的稳定性和有效性。方法对云南省肿瘤医院2012年3月至2013年11月收治的112例脑肿瘤住院患者进行生命质量测定,采用一般资料调查表和QLICP-BN(V1.0)进行数据收集。检验量表的信度、效度、反应度,进而对量表的测量学特征进行评价。结果该量表总分的分半信度为0.95,克朗巴赫系数α为0.92,重测相关系数r为0.78;脑肿瘤特异模块经主成分法提取公因子并经方差最大旋转后,得到3个主成分,累计方差贡献率为64.18%;治疗前特异模块得分为75.30±17.44,治疗后特异模块得分为78.91±12.20,差异有统计学意义(t=-2.481,P=0.015),治疗前量表总得分为65.26±12.29,治疗后量表总得分为69.62±10.41,差异有统计学意义(t=-4.492,P<0.001);量表总反应度为0.456,显示反应度适中。结论QLICP-BN(V1.0)具有良好的信度及效度、一定的反应度,可作为我国脑肿瘤患者生命质量的测量工具。

Objective To understand the reliability and validity of quality of life instruments for cancer patients-brain neoplasm[QLICP-BN(V1.0)],a self-developed quality of life scale for cancer patients.Methods The quality of life of 112 patients with brain neoplasms in Yunnan Cancer Hospital from March 2012 to November 2013 was measured.The general data questionnaire and QLICP-BN(V1.0)were used for data collection.The reliability,validity and responsiveness of the scale were tested,and then the metric characteristics of the scale were evaluated.Results The split-half reliability of the total score of the scale was 0.95,the Cronbachαcoefficient was 0.92,and the test-retest correlation coefficient rwas 0.78.After extracting common factors by the principal component method and rotating with the maximum variance,the specific module obtained three principal components,and the cumulative variance contribution rate was 64.18%.The score of specific module was 75.30±17.44 before treatment and 78.91±12.20 after treatment(t=-2.481,P=0.015).The total score of scale before treatment was 65.26±12.29,and that after treatment was 69.62±10.41,with a statistically significant difference(t=-4.492,P<0.001).The total responsiveness of the scale was 0.456,showing moderate responsiveness.Conclusion QLICP-BN(V1.0)has good reliability,validity and a certain degree of responsiveness.It can be used as a measurement tool for the quality of life of patients with brain neoplasms in China.